POST Online Media Lite Edition


Pfizer updates guidance, expects diluted EPS to be $1.29-$1.38

Staff writer |
Pfizer announced updates to certain components of its 2015 financial guidance solely to reflect the impact of the recently completed acquisition of Hospira.

Article continues below

On September 3, 2015, Pfizer completed the acquisition of Hospira. Pfizer's fiscal year-end for international subsidiaries is November 30, 2015, and Pfizer's fiscal year-end for U.S. subsidiaries is December 31, 2015.

Consequently, Pfizer's 2015 financial results will include approximately three months of legacy Hospira international operations and approximately four months of legacy Hospira U.S. operations.

Financial results for Pfizer's third-quarter 2015 and nine-months ended September 27, 2015 will reflect approximately one month of legacy Hospira U.S. operations but will not include financial results from legacy Hospira international operations.

The ranges for certain components of Pfizer's 2015 financial guidance are: reported revenues $46.5 to $47.5 billion (previously $45 to $46 billion), reported diluted EPS $1.29 to $1.38 (previously $1.38 to $1.47), and adjusted diluted EPS $2.04 to $2.10 (previously $2.01 to $2.07).

What to read next

Allergan expects non-GAAP diluted EPS between $1.76 and $1.78
Burlington Stores increases guidance for Q4 and fiscal year
HanesBrands Q1 net sales $1.38 billion